$11.340
+0.792 (+6.98%)收盤時
MOBI 資訊
MOBI 事件
Mobia Medical's VNS System Recognized by American Heart Association
Mobia Medical announced that implantable paired Vagus Nerve Stimulation, or VNS, has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the American Heart Association and American Stroke Association, published August 27 in Stroke as a treatment option to improve upper-limb function and impairment for chronic stroke survivors. The new guideline states that VNS paired with high-dose task-specific training may be considered to improve upper-limb function and impairment for eligible patients. Mobia Medical's Vivistim Paired VNS System is the only FDA-approved system that delivers this treatment approach. "Recognition of paired VNS in the guideline for stroke recovery is a meaningful validation of the impact of our technology, which is grounded in our evidence-based approach to long-term stroke recovery," said Richard Foust, president and CEO of Mobia Medical. "This is an important step in our mission to improve the standard of care for stroke survivors, and we're committed to continuing to build the evidence base that supports it."
Mobia Medical Publishes Two-Year Follow-Up Data from VNS-REHAB Study
Mobia Medical announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the official peer-reviewed journal of the American Academy of Neurology. The findings demonstrate that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, ability to perform activities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim Paired VNS Therapy. With its publication, this data now represents some of the most comprehensive longitudinal evidence to date for any intervention approved for chronic ischemic stroke recovery. The two-year follow-up data, published in Neurology, reports outcomes from 49 participants in the VNS-REHAB pivotal trial, demonstrating a high responder rate and substantial improvements in impairment and function including: Clinically meaningful response on the Fugl-Meyer Assessment of Upper Extremity impairment and/or the Wolf Motor Function Test in 76% of participants. Average improvement of +7.5 points from baseline on the FMA-UE, exceeding the minimum clinically important difference of 6 points. Average improvement of +0.63 from baseline on the WMFT, exceeding the MCID of 0.4 points. These upper-limb motor improvements also translated into impactful real-world changes in the daily lives of stroke survivors. Participants demonstrated statistically significant and clinically meaningful improvements across multiple patient-reported measures of activity, participation, and quality of life, including: Ability to perform activities of daily living, such as bathing and dressing. Perceived ease of performing daily activities with the affected hand and arm, such as carrying heavy objects or tying shoelaces. Amount of use and quality of movement of the affected hand and arm when performing activities of daily living, such as brushing teeth or typing. Overall stroke-specific quality of life, such as mood, self-care, social participation and family roles. The study also captures positive three-year outcomes from 16 participants, providing further supporting evidence that the benefits are durable and maintained long-term. Additionally, a subset of the 49 total participants experienced further improvement in scores between years one and two, suggesting that recovery may continue over time with ongoing self-directed Vivistim Therapy.
Mobia Medical Inc Trading Halted
Mobia Medical Inc trading halted, volatility trading pause
Mobia Medical, Odyssey Therapeutics and Others Go Public This Week
New listings continued to roll out this week, with Mobia Medical, Odyssey Therapeutics, Suja Life, and HawkEye 360 all making their public market debuts.LATEST IPOS AND DIRECT LISTINGS:Mobia Medicalopened on May 8 at $14. The company priced 10M shares at $15.00. The deal priced at the midpoint of the $14.00-$16.00 range. Mobia is a commercial-stage medical device company that says it is "redefining stroke recovery for survivors living with life-altering motor impairments."Odyssey Therapeuticsopened on May 8 at $20. The company priced 15.5M shares at $18.00. The deal size was increased to 15.5M shares from 13.2M and priced at the top end of the $16.00-$18.00 range. Odyssey is a clinical-stage biopharmaceutical company that says it is "seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology."Suja Lifeopened on May 7 at $18.00. The company priced 8.89M shares at $21.00. The deal priced at the low-end of the $21.00-$24.00 range. Suja Life is a maker of organic, cold-pressed juices, wellness shots, and "better-for-you" sodas.HawkEye 360opened on May 7 at $33.80. The company priced 16M shares at $26.00. The deal priced at the high-end of the $24.00-$26.00 range. HawkEye 360 delivers space-based collection, proprietary signal processing, and AI-powered analytics to the U.S. Government and allied partners.RECENT SPAC IPOS:Starlink AI Acquisitionopened on May 8 at $10.00. The blank check company intends to conduct a search for target businesses without being limited to a particular industry.Shreya Acquisition Groupopened on May 7 at $10.00. The blank check company intends to focus on companies engaged in the health and wellness, hospitality, media and entertainment, shipping infrastructure and waterways tourism sectors.Vernal Capital Acquisitionopened on May 6 at $10. D. Boral Capital is acting as sole book-running manager of the offering.PERFORMANCE:Prices as of 11:00 am ET on Monday, May 11 -Mobia Medical – down over 2% at $11.50;Odyssey Therapeutics – up almost 4% at $17;Suja Life – down 1% at $17.66;HawkEye 360 – down about 3% at $32.46.RECENT IPOS TO WATCH:Madison Airand Arxisare already seeing coverage roll out, while AEVEX, Alamar Biosciencesand Kailera Therapeuticsare among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Inspire Brands, Csquare, Tarsier Pharma, and Quantinuum.Clickto see upcoming IPO calendar on TipRanks.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses. Inspire is a multi-brand restaurant company whose portfolio includes the Dunkin' Donuts, Arby's, Buffalo Wild Wings, Sonic Drive-In, Jimmy John's and Baskin-Robbins chains.Csquarefiled confidentially for a U.S. initial public offering, a signal that more data center companies are lining up to sell shares for the first time over the coming year, Bloomberg's Bailey Lipschultz. The provider of colocation and data center services announced on Friday that it had submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission. The Brookfield Infrastructure Partners-backed company joins a rush of new listings as the companies building out the backbone to support AI's energy needs seek to raise funds, the author notes.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated, "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial... Although we are still early in this journey, I believe we have the technology, the team, the discipline, and the persistence required to build an enduring company."Honeywellannounced thatQuantinuumhas publicly filed a registration statement on Form S-1 with the U.S. SEC relating to a proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Quantinuum intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "QNT." J.P. Morgan and Morgan Stanley are acting as joint lead active book-running managers for the proposed offering. Jefferies and Evercore ISI are also acting as active book-running managers.OTHER IPO NEWS:SpaceX's IPO filing indicates governance provisions that would give Elon Musk near-total control through supervoting shares and other restrictive measures, significantly limiting typical shareholder rights and avenues for investor oversight, Reuters' Anirban Sen, Ross Kerber and Suzanne McGee."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Mobia Medical Prices 10M Shares at $15.00
Mobia Medical priced 10M shares at $15.00. The deal priced at the midpoint of the $14.00-$16.00 range. Mobia is a commercial-stage medical device company that says it is "redefining stroke recovery for survivors living with life-altering motor impairments."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。